Enhancing Cancer Treatment with AQ4N and Tirapazamine
Author Information
Author(s): Friery O P, Gallagher R, Murray M M, Hughes C M, Galligan E S, McIntyre I A, Patterson L H, Hirst D G, McKeown S R
Primary Institution: Radiation Science Research Group, School of Biomedical Sciences, University of Ulster at Jordanstown
Hypothesis
The bioreductive drugs AQ4N and tirapazamine can enhance the anti-tumour effect of cyclophosphamide.
Conclusion
AQ4N provided a better anti-tumour effect than tirapazamine when used with cyclophosphamide.
Supporting Evidence
- AQ4N combined with cyclophosphamide produced effects equivalent to a higher dose of cyclophosphamide alone.
- Tirapazamine also enhanced the effect of cyclophosphamide but was less effective than AQ4N.
- AQ4N did not increase toxicity to bone marrow cells compared to cyclophosphamide alone.
Takeaway
This study tested two drugs, AQ4N and tirapazamine, to see if they could make a cancer treatment stronger. AQ4N worked better without hurting healthy cells.
Methodology
The study assessed the effects of AQ4N and tirapazamine in combination with cyclophosphamide in three murine tumour models.
Participant Demographics
Male BDF and C3H mice were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website